News for 'Sun Pharma'

Why is entire system working to help pharma companies, asks SC

Why is entire system working to help pharma companies, asks SC

Rediff.com27 Oct 2026

The Supreme Court has strongly criticised the Centre and pharmaceutical manufacturers over the significant disparity between the Maximum Retail Price (MRP) of medicines and their price to retailers, questioning the justification for such high margins and the perceived ineffectiveness of the National Pharmaceutical Pricing Authority (NPPA). The court reserved its verdict on petitions seeking strict price control and prevention of unethical overpricing of essential medicines.

Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies

Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies

Rediff.com22 Sep 2026

India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies.

Pharma companies can claim GST input tax credit on free samples, expired goods from FY'28

Pharma companies can claim GST input tax credit on free samples, expired goods from FY'28

Rediff.com9 Oct 2026

The GST Council has approved a proposal allowing pharmaceutical companies to claim Input Tax Credit (ITC) on free samples and goods destroyed or written off due to expiry, effective from the next fiscal year. This move aims to support manufacturing, liquidity, and exports within the sector.

Muhurat Trading: Sensex, Nifty Begin Samvat 2083 with Gains

Muhurat Trading: Sensex, Nifty Begin Samvat 2083 with Gains

Rediff.com8 Nov 2026

Indian benchmark indices Sensex and Nifty opened the special Muhurat trading session on a bullish note, marking the beginning of the Hindu calendar Samvat 2083, driven by buying in key blue-chip stocks.

Stock Markets Today: Sensex, Nifty Up on Gains in IT Stocks

Stock Markets Today: Sensex, Nifty Up on Gains in IT Stocks

Rediff.com30 Oct 2026

Indian benchmark indices Sensex and Nifty extended their rally in early trade, driven by strong buying in IT firms and an earnings-driven surge in Tata Group's retail arm, Trent, which reported a 25 per cent increase in net profit.

Stock Markets Today: Sensex, Nifty Gain on FII Inflows, Lower Crude Prices

Stock Markets Today: Sensex, Nifty Gain on FII Inflows, Lower Crude Prices

Rediff.com12 Nov 2026

Indian benchmark equity indices, Sensex and Nifty, rallied in early trade, driven by sustained foreign fund inflows and a decline in crude oil prices. Foreign Institutional Investors (FIIs) have shown aggressive buying, investing a significant amount in Indian equities, while positive Q2 earnings and lower Brent crude prices are further supporting the market's upward trend. Track Sensex, Nifty on November 12, 2026.

Stock Markets Today: Sensex, Nifty fall as inflation concerns weigh on markets

Stock Markets Today: Sensex, Nifty fall as inflation concerns weigh on markets

Rediff.com13 Nov 2026

Indian equity benchmark indices Sensex and Nifty slumped in early trade, ending a three-day rally, as profit-taking combined with concerns over surging retail inflation, which breached the Reserve Bank of India's upper tolerance limit, leading to anticipation of a policy rate hike. Track Sensex, Nifty on November 13.

AI Reshapes Software Engineering: Review, Don't Just Write Code

AI Reshapes Software Engineering: Review, Don't Just Write Code

Rediff.com5 days ago

Infosys co-founder S Gopalakrishnan states that software engineers must now be retrained to review and certify AI-written code, as AI has automated coding. He emphasises that AI-generated code cannot be fully trusted and requires human oversight. Gopalakrishnan also highlights that IT services and outsourcing will continue, and AI presents significant opportunities for new products and services, particularly for India and startups.

NPPA slashes prices of 543 anti-cancer medicines from Nov 9

NPPA slashes prices of 543 anti-cancer medicines from Nov 9

Rediff.com29 Oct 2026

India's drug price regulator, NPPA, has revised downward the maximum retail price of 543 anti-cancer medicines, effective November 9. This follows an announcement enforcing trade margin rationalisation on 137 non-scheduled anti-cancer drugs, leading to significant price drops for several key brands.

Indian Equities End Flat as Elevated Crude, US Fed Decision Weigh

Indian Equities End Flat as Elevated Crude, US Fed Decision Weigh

Rediff.com27 Oct 2026

Indian benchmark indices, Sensex and Nifty, closed largely unchanged after a volatile trading session, influenced by persistently high crude oil prices, selling pressure in major bank stocks, and investor caution ahead of the US Federal Reserve's policy decision.

IT Stocks Gain Rs 25,029 Crore

IT Stocks Gain Rs 25,029 Crore

Rediff.com15 Oct 2026

Pharma stocks lost Rs 25,169 crore.

How Gen Z Will Drive The Future Of AI And Green Innovation

How Gen Z Will Drive The Future Of AI And Green Innovation

Rediff.com23 Oct 2026

Telangana IT Minister D Sridhar Babu stated that Gen Z will be the driving force behind the next wave of AI and green innovation. He urged young innovators to use their skills to solve real-world challenges, particularly in sustainability. The launch of the Green Skills and Applied AI Centre of Excellence in Hyderabad, a partnership between Telangana's IT Ministry, Microsoft, 1M1B, and MeitY Startup Hub, aims to equip graduates with industry-relevant skills in AI, green pharma, solar energy, EVs, and wind energy, with 100 job offers already announced.

Muhurat Trading: Sensex, Nifty End Marginally Lower After Seven-Day Rally

Muhurat Trading: Sensex, Nifty End Marginally Lower After Seven-Day Rally

Rediff.com8 Nov 2026

Indian benchmark indices Sensex and Nifty ended marginally lower in the special Diwali Muhurat trading session, snapping a seven-day rally amid profit-taking by investors. Despite a positive start, the Sensex dipped 28.62 points to 80,999.40, and the Nifty declined 43.95 points to 24,986.40.

US Fed rate decision, corporate earnings, crude oil to steer market sentiment

US Fed rate decision, corporate earnings, crude oil to steer market sentiment

Rediff.com25 Oct 2026

Indian stock markets are set to be influenced this week by a confluence of factors including quarterly corporate earnings, the US Federal Reserve's interest rate decision, fluctuations in crude oil prices, and ongoing geopolitical developments in West Asia.

Weakest Samvat in 15 years ends on a high for markets

Weakest Samvat in 15 years ends on a high for markets

Rediff.com7 Nov 2026

Indian equity markets, represented by the Sensex and Nifty 50, concluded Samvat 2082 with significant weekly gains, marking their strongest performance in nearly six years, despite it being their weakest Samvat in 15 years overall. The late recovery was driven by hopes of tax changes, resilient corporate earnings, and easing geopolitical tensions.

Stock Markets Today: Sensex, Nifty extend rally on falling crude prices and FII inflows

Stock Markets Today: Sensex, Nifty extend rally on falling crude prices and FII inflows

Rediff.com3 Nov 2026

Indian benchmark indices Sensex and Nifty extended their winning streak in early trade, with Sensex jumping 614.66 points and Nifty rallying 149.80 points. This surge is attributed to a sharp correction in crude oil prices, continued foreign fund inflows, and positive Q2 results, creating an ideal environment for the market rally to continue.

Stock Markets Today: Sensex. Nifty Surge on Reliance Boost

Stock Markets Today: Sensex. Nifty Surge on Reliance Boost

Rediff.com2 Nov 2026

Indian benchmark indices, Sensex and Nifty, saw significant gains in early trade, primarily driven by a strong performance from Reliance Industries following its record quarterly profit announcement and a notable decline in global crude oil prices. Positive foreign fund inflows and a buoyant trend in Asian markets further contributed to the market's optimism.Track Sensex, Nifty on November 2.

Reliance-led rally, falling crude oil prices drive Sensex up 1,233 points

Reliance-led rally, falling crude oil prices drive Sensex up 1,233 points

Rediff.com2 Nov 2026

Indian benchmark indices, Sensex and Nifty, closed significantly higher, with the Sensex rallying 1,233 points and the Nifty climbing to 23,440.80. This surge was primarily fuelled by a sharp increase in Reliance Industries' share price following strong quarterly earnings and a notable decline in crude oil prices.

Indian Pharma Bets Beyond US Generics

Indian Pharma Bets Beyond US Generics

Rediff.com26 Jun 2026

Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.

Cancer Drug Price Cuts May Bypass PAP Patients

Cancer Drug Price Cuts May Bypass PAP Patients

Rediff.com3 Nov 2026

PAPs can reduce expenditure by 30 to 60 per cent for some expensive immunotherapies and targeted therapies.

Stock Markets Today: Sensex, Nifty Decline as Crude Prices, Geopolitical Risks Weigh on Sentiments

Stock Markets Today: Sensex, Nifty Decline as Crude Prices, Geopolitical Risks Weigh on Sentiments

Rediff.com26 Oct 2026

Indian benchmark equity indices, Sensex and Nifty, experienced a decline in early trade due to elevated crude oil prices, ongoing geopolitical uncertainties, and investor caution ahead of the US Federal Reserve's policy decision later this week. Track Sensex, Nifty on October 26.

Torrent Pharma's India Business and Margin Expansion Fuel Brokerage Confidence

Torrent Pharma's India Business and Margin Expansion Fuel Brokerage Confidence

Rediff.com22 Jun 2026

Torrent Pharma has emerged as a top sectoral pick for brokerages, driven by healthy growth in India revenues and improved gross margins, leading to a 44 per cent stock return over the past year.

MRPs of 543 cancer drugs cut by up to 93%, but expensive innovator medicines untouched

MRPs of 543 cancer drugs cut by up to 93%, but expensive innovator medicines untouched

Rediff.com29 Oct 2026

India's drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has significantly reduced the maximum retail prices (MRPs) of 543 cancer drug brands and pack sizes, with some reductions reaching up to 93 per cent. However, expensive innovator drugs from multinational corporations, including high-selling Bevacizumab and immunotherapy Keytruda, remain unaffected, highlighting limitations in the price control intervention.

Mahindra's Bristlecone Targets Billion-Dollar Valuation With 24% Growth

Mahindra's Bristlecone Targets Billion-Dollar Valuation With 24% Growth

Rediff.com27 Oct 2026

Bristlecone, a Mahindra Group company, reported a 24% year-on-year topline growth and aims for a billion-dollar valuation. The AI-powered supply chain services provider is expanding its offerings to include data analytics, AI, and product engineering, focusing on making supply chains more resilient for its global clients across high-tech, retail, manufacturing, and life sciences segments.

Mahindra's Bristlecone Eyes Billion-Dollar Valuation With 24% Growth

Mahindra's Bristlecone Eyes Billion-Dollar Valuation With 24% Growth

Rediff.com25 Oct 2026

Mahindra Group's Bristlecone, a supply chain services provider, has reported a 24 per cent year-on-year topline growth and aims for a billion-dollar valuation. The company is expanding its offerings in AI, data analytics, and product engineering, focusing on resilient supply chains for global enterprises.

Stock Markets Today: Sensex, Nifty Pared Early Losses in Volatile Trade

Stock Markets Today: Sensex, Nifty Pared Early Losses in Volatile Trade

Rediff.com14 Oct 2026

Indian benchmark indices, Sensex and Nifty, recovered early losses on Wednesday, driven by strong buying in IT stocks and HDFC Bank, sustaining the previous session's recovery despite FII outflows. Track Sensex, Nifty on October 14.

Key Accomplice Arrested In Major Counterfeit Drug Racket

Key Accomplice Arrested In Major Counterfeit Drug Racket

Rediff.com30 Sep 2026

Police in Bengaluru have arrested Balasubramanian, a partner in DM Pharma, in connection with an interstate counterfeit drug racket. This arrest follows the apprehension of alleged kingpin Prashanth Rajan Babu. The Special Investigation Team is probing the supply chain, financial transactions, and distribution channels of fake medicines worth nearly Rs 5 crore, which were being relabelled as premium brands.

'Carnage': SC on 10x markup on cancer drugs, bats for 16pc margin

'Carnage': SC on 10x markup on cancer drugs, bats for 16pc margin

Rediff.com29 Sep 2026

The Supreme Court has strongly criticised the exorbitant markup on cancer drugs by hospitals, calling it "carnage" and "broad daylight dacoity." The court highlighted a case where a cancer drug was marked up ten times its retail price and urged the Centre to implement a uniform 16% margin on all medicines. It also raised concerns about hospitals forcing patients to buy medicines from their in-house chemists.

Why This Doctor Is Fighting For Affordable Medicines

Why This Doctor Is Fighting For Affordable Medicines

Rediff.com30 Oct 2026

'I have seen in Agra parents selling their buffalo, which is their sole source of livelihood, to buy expensive medicines to treat their child.' 'I was very moved by such cases and therefore approached the court to regulate the price of medicines in our country.'

Sun Pharma sees 27% profit surge in Q1FY27, driven by India and innovative medicines

Sun Pharma sees 27% profit surge in Q1FY27, driven by India and innovative medicines

Rediff.com1 Aug 2026

Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.

Has India Fallen Out Of Love With Weight-Loss Drugs?

Has India Fallen Out Of Love With Weight-Loss Drugs?

Rediff.com21 Oct 2026

More patients can now afford semaglutide, but the early excitement around the drug is fading.

Sun Pharma US generics biz remains under pressure

Sun Pharma US generics biz remains under pressure

Rediff.com23 May 2026

Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.

Indian IT stocks record best week in 18 years amid global AI sell-off

Indian IT stocks record best week in 18 years amid global AI sell-off

Rediff.com17 Oct 2026

Indian IT stocks have experienced their most significant weekly surge in 18 years, with the Nifty IT index climbing 11.72 per cent, as a global sell-off in AI-linked equities redirected investor attention towards India's IT services sector. This shift aligns with a JP Morgan report identifying India as a 'natural AI hedge' due to its large, liquid market and strong domestic institutional investor base.

Sensex, Nifty fall despite global cues; IT, financials lead decline

Sensex, Nifty fall despite global cues; IT, financials lead decline

Rediff.com22 Sep 2026

Indian benchmark indices, Sensex and Nifty, closed lower on Tuesday, with the Sensex declining 329.91 points to 74,529.08 and the Nifty dipping 85.30 points to 23,329, primarily dragged by underperformance in IT, financial, and capital goods stocks despite positive global market trends and easing crude oil prices.

Lupin eyes $500 million from biosimilars, expands global footprint

Lupin eyes $500 million from biosimilars, expands global footprint

Rediff.com15 Sep 2026

Pharma major Lupin is significantly increasing its focus on biosimilars, aiming for a turnover of nearly $500 million from this segment over the next five years, driven by new product launches and expanded presence in key global markets like the US, Europe, and Japan.

Cipla faces fresh FDA blow, Pune warehouse drug licences cancelled

Cipla faces fresh FDA blow, Pune warehouse drug licences cancelled

Rediff.com2 Oct 2026

The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale and distribution licences of Cipla Pharma & Life Sciences Ltd's carrying and forwarding (C&F) warehouse in Pune. This action follows alleged violations related to packaging, storage, documentation, and recall of Reactin Plus Tablets, a Schedule H drug. The FDA cited issues like misbranding, inadequate storage conditions, and deficiencies in record-keeping, reiterating its commitment to ensuring medicine safety and compliance.

How Much Did FPIs Sell In September?

How Much Did FPIs Sell In September?

Rediff.com8 Oct 2026

They had bought Rs 29,631 crore worth of shares in August.

Stock Markets Today: Sensex, Nifty Recover as Oil Prices Moderate; IT Sector Leads Gains

Stock Markets Today: Sensex, Nifty Recover as Oil Prices Moderate; IT Sector Leads Gains

Rediff.com30 Sep 2026

Indian benchmark indices Sensex and Nifty rebounded in early trade after two days of losses, driven by easing crude oil prices and strong buying in blue-chip IT stocks, despite continued global uncertainties. Track Sensex, Nifty on September 30.

HSBC emerges as top international bank for Indian corporate fundraising

HSBC emerges as top international bank for Indian corporate fundraising

Rediff.com12 Oct 2026

HSBC has emerged as the leading international bank in facilitating fundraising for Indian companies through bonds, syndicated loans, and IPOs during January-September 2026, according to Hitendra Dave, CEO of HSBC India.

Stock Markets Today: Sensex, Nifty Jump on Global Cues

Stock Markets Today: Sensex, Nifty Jump on Global Cues

Rediff.com5 Oct 2026

Indian benchmark indices Sensex and Nifty saw a significant rebound in early trade, with the Sensex surging over 700 points, driven by a decline in crude oil prices, easing concerns over Federal Reserve tightening, and the appointment of Anup Bagchi as the new MD and CEO of HDFC Bank.